Zonisamide (DB00909): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Zonisamide is a second-generation, broad-spectrum antiepileptic drug (AED) distinguished by its unique 1,2-benzisoxazole chemical structure and its classification as a sulfonamide.[1] Its therapeutic efficacy is attributed to a multi-modal mechanism of action that is not yet fully elucidated but is primarily understood to involve the blockade of voltage-gated sodium channels and low-threshold (T-type) calcium channels. These primary actions are complemented by secondary modulatory effects on major neurotransmitter systems, including the GABAergic, glutamatergic, dopaminergic, and serotonergic pathways.[1]

The primary approved indication for zonisamide in the United States and Europe is as an adjunctive therapy for the treatment of partial-onset seizures in adults and, in some jurisdictions, older pediatric patients.[1] The drug's pharmacokinetic profile is notable for its high oral bioavailability, exceptionally long elimination half-life, and extensive, saturable binding to erythrocytes, which acts as a significant drug reservoir and necessitates a prolonged period to achieve steady-state concentrations.[2]

The clinical use of zonisamide must be carefully balanced against its significant safety considerations, which are mechanistically linked to its fundamental chemical properties. As a sulfonamide, it carries a risk of severe and potentially fatal hypersensitivity reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Furthermore, its weak but clinically relevant activity as a carbonic anhydrase inhibitor predisposes patients to metabolic acidosis and nephrolithiasis, requiring diligent monitoring.[11] This monograph provides an exhaustive review of zonisamide's chemistry, pharmacology, clinical efficacy, and safety profile to guide its optimal use in clinical practice.

Section 1: Introduction and Developmental History

The clinical availability and therapeutic application of zonisamide have been shaped by a protracted and fragmented developmental history spanning several decades and multiple corporate entities. This complex journey from its initial discovery in Japan to its eventual, staggered approval in Western markets has resulted in significant regional disparities in its approved indications and has influenced its perception within the global medical community.

1.1 Discovery and Early Development in Japan

Zonisamide was first synthesized by Uno and colleagues at Dainippon Pharmaceutical (now Dainippon Sumitomo Pharma) in Japan in 1972.[13] The initial line of inquiry for the compound was not for epilepsy but for the treatment of psychiatric diseases.[6] However, subsequent preclinical screening revealed its potent anticonvulsant properties. In the maximal electroshock (MES) test, a standard preclinical model for identifying agents that prevent seizure spread and are effective against generalized tonic-clonic seizures, zonisamide demonstrated efficacy comparable to that of established AEDs like phenobarbital and carbamazepine.[14] This early evidence established its potential as a broad-spectrum anticonvulsant. Following successful clinical development, Dainippon launched the drug in Japan in 1989 under the brand name Excegran for the treatment of epilepsy.[1] It gained approval in Korea shortly thereafter in 1990.[18]

1.2 A Fractured Path to Western Markets

The introduction of zonisamide into Western markets was considerably more complicated and delayed. Initial development in the United States was undertaken by Warner-Lambert/Parke-Davis, which, for reasons not fully detailed in the public record, discontinued its program in 1987.[18] Dainippon then re-assumed responsibility for development in the US, conducting further studies until 1997. At that point, the rights to zonisamide were acquired by Athena Neurosciences, a company that would later become part of Elan Pharmaceuticals.[18]

The path to European approval was similarly fraught. A Marketing Authorisation Application submitted to European regulators in 1997 was ultimately withdrawn. The Committee for Proprietary Medicinal Products (CPMP) identified major deficiencies in the dossier, notably that the pivotal clinical trials submitted were of insufficient duration to adequately assess long-term efficacy, reflecting the increasingly stringent regulatory standards in Europe.[18]

After this setback, Elan Pharmaceuticals successfully navigated the US regulatory process, securing Food and Drug Administration (FDA) approval for Zonegran (zonisamide) on March 1, 2000. The approved indication was for adjunctive therapy in the treatment of partial-onset seizures in adults.[1] European approval did not follow until 2005, a full 16 years after its Japanese debut.[1] In 2004, Elan transferred its interests in zonisamide to Eisai Co., Ltd., which has since managed the marketing of the drug in the United States, Europe, and various countries in Asia.[13]

1.3 Divergent Indications and Post-Approval Developments

The long and separate development timelines in Japan versus the West fostered an environment where clinical experience and research priorities diverged. This divergence is most clearly illustrated by the approval of zonisamide for the treatment of Parkinson's disease (PD) in Japan. This indication, granted in 2009 as an adjunctive therapy to levodopa, reportedly stemmed from a serendipitous clinical observation in a patient who had both epilepsy and PD.[13] With nearly a decade of post-marketing experience before the drug was even approved in the US, Japanese clinicians and the local developer, Dainippon, were uniquely positioned to identify and formally investigate this novel therapeutic effect. In contrast, Western development, managed by different companies and facing stricter regulatory hurdles, remained narrowly focused on establishing efficacy in epilepsy to meet the demands of the FDA and the European Medicines Agency (EMA). Consequently, the use of zonisamide for PD remains an off-label or investigational application in most of the world.[21]

A more recent significant development occurred in July 2022, when the FDA approved ZONISADE™, the first oral suspension formulation of zonisamide.[22] Developed by Eton Pharmaceuticals and commercialized by Azurity Pharmaceuticals, this new formulation was designed to address the long-standing clinical challenge of administering the drug to patients with dysphagia, including certain pediatric and geriatric populations, who are unable to swallow the solid capsule form.[23]

Section 2: Physicochemical Properties and Formulations

The therapeutic application and pharmaceutical development of zonisamide are fundamentally governed by its distinct chemical structure and physical properties. These characteristics have dictated its formulation, influenced its stability, and provided the basis for its classification as a unique antiepileptic agent.

2.1 Chemical Identity and Structure

Zonisamide is a synthetic small molecule identified chemically as 1,2-benzisoxazole-3-methanesulfonamide.[1] It is classified as a sulfonamide due to the presence of a sulfamoyl group (

−SO2​NH2​) but is structurally unrelated to other sulfonamide-containing AEDs or to other classes of antiepileptic agents.[1] The core of the molecule is a 1,2-benzisoxazole ring system. Zonisamide does not contain any chiral centers or optically active centers and therefore does not exhibit optical isomerism.[18]

Its molecular formula is C8​H8​N2​O3​S, corresponding to a molecular weight of 212.23 g/mol.[1] The compound is registered under the Chemical Abstracts Service (CAS) Number 68291-97-4 and has been assigned the DrugBank accession number DB00909.[1] A consolidated table of its key chemical and physical properties is provided below (Table 1).

2.2 Physical and Chemical Properties

Zonisamide exists as a white to pale yellow crystalline powder or as white needles.[1] It is reported to be both odorless and tasteless.[1] The compound is very slightly or moderately soluble in water, with a reported solubility of approximately 0.80 mg/mL.[1] Its solubility in 0.1 N HCl is slightly lower, at 0.50 mg/mL.[16] It is more readily soluble in organic solvents such as methanol, ethanol, and ethyl acetate.[1]

The melting point is consistently reported in the range of 161–165 °C [1], although some sources indicate decomposition occurs at a much higher temperature of 275 °C.[2] Zonisamide is a weak acid with a dissociation constant (

pKa) of 10.2.[1] It is described as a very stable and non-hygroscopic compound, which simplifies its storage and handling.[18]

2.3 Pharmaceutical Formulations

The inherent physicochemical properties of zonisamide have been the primary determinants of its pharmaceutical formulation. The combination of poor water solubility and a bitter taste presented a challenge for developing a palatable and bioavailable oral dosage form. This challenge directly led to the development of hard gelatin capsules as the initial and, for many years, the only available formulation. This approach effectively masked the taste and, through optimization of drug particle size and the use of suitable excipients, achieved adequate dissolution and bioavailability.[18]

For over two decades following its US approval, this capsule-only availability created a significant clinical gap for patient populations with difficulty swallowing, such as young children, the elderly, and those with neurological or physical impairments causing dysphagia. This long-standing unmet need was finally addressed in 2022 with the introduction of a liquid formulation.

The currently available formulations are:

• Capsules (Zonegran® and generics): Hard gelatin capsules available in 25 mg, 50 mg, and 100 mg strengths.[6] These formulations contain inactive ingredients such as microcrystalline cellulose, hydrogenated vegetable oil, gelatin, and various colorants.[18]
• Oral Suspension (Zonisade™): An oral liquid formulation providing a concentration of 100 mg per 5 mL, approved in the US in July 2022.[22] This formulation is specifically intended to improve administration and adherence for patients who cannot take solid dosage forms.[23]

Table 1: Physical and Chemical Properties of Zonisamide

Property	Value / Identifier	Source(s)
IUPAC Name	1,2-benzoxazol-3-ylmethanesulfonamide	1
Chemical Formula	C8​H8​N2​O3​S	1
Molecular Weight	212.23 g/mol	1
CAS Number	68291-97-4	1
DrugBank ID	DB00909	1
InChIKey	UBQNRHZMVUUOMG-UHFFFAOYSA-N	1
SMILES	C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N	1
Physical State	Crystalline solid / powder	14
Color	White to pale yellow	1
Melting Point	161-165 °C	1
pKa	10.2	1
Water Solubility	0.80 mg/mL	16
LogP	0.5	1

Section 3: In-Depth Pharmacology

Zonisamide's clinical utility is derived from a complex and multi-modal pharmacological profile. While its precise mechanism of action remains to be fully elucidated, its anticonvulsant effects are believed to result from a combination of actions on voltage-gated ion channels, modulation of several major neurotransmitter systems, and weak enzymatic inhibition. This multifaceted activity may explain its broad-spectrum efficacy, particularly in patients with epilepsy refractory to other agents.[5] Its unique pharmacokinetic properties, especially its distribution and long half-life, are critical determinants of its clinical use.

3.1 Mechanism of Action (MOA)

Zonisamide exerts its therapeutic effects through several distinct but complementary mechanisms.

3.1.1 Primary Ion Channel Blockade

The principal antiepileptic actions of zonisamide are attributed to its effects on neuronal ion channels.

• Voltage-Gated Sodium Channels: Zonisamide produces a use-dependent block of voltage-sensitive sodium channels. By altering the fast inactivation kinetics of these channels, it reduces sustained, high-frequency repetitive firing of action potentials, which is a hallmark of seizure activity. This action effectively stabilizes neuronal membranes and suppresses neuronal hypersynchronization.[1]
• T-Type Calcium Channels: The drug also inhibits low-threshold, transient inward calcium currents, known as T-type calcium currents.[1] This mechanism is thought to contribute to its ability to prevent the propagation and spread of seizure discharges across neuronal networks and may be particularly relevant to its efficacy in certain generalized seizure types, such as absence seizures.[5] In vitro studies have shown that zonisamide does not significantly affect high-threshold L-type calcium currents.[9]

3.1.2 Modulation of Neurotransmitter Systems

Zonisamide also influences several key neurotransmitter systems, although the clinical significance of these actions is less defined than its effects on ion channels.

• GABAergic System: The drug appears to enhance GABAergic inhibitory neurotransmission, though the mechanism is not straightforward. It binds allosterically to the GABA/benzodiazepine receptor-ionophore complex, but this binding does not directly alter chloride ion flux.[1] Furthermore, it does not appear to potentiate the postsynaptic activity of GABA or affect its neuronal or glial uptake.[9] Some evidence suggests it may facilitate GABA release.[5]
• Glutamatergic System: Zonisamide may suppress excitatory neurotransmission by inhibiting the release of glutamate.[1]
• Monoaminergic Systems: In vivo microdialysis studies have demonstrated that zonisamide facilitates both dopaminergic and serotonergic neurotransmission.[9] These effects on monoamines are thought to contribute to some of its neuropsychiatric side effects as well as its observed therapeutic utility in treating the motor symptoms of Parkinson's disease.[14]

3.1.3 Carbonic Anhydrase (CA) Inhibition

Zonisamide is a weak inhibitor of the enzyme carbonic anhydrase, with activity against several human isoforms, including CA-I, CA-II, and CA-V.[1] While this property was initially thought to be a primary mechanism, similar to the sulfonamide AED acetazolamide, it is now widely accepted that this action is not a major contributor to zonisamide's primary

antiepileptic effects.[4] However, this weak enzymatic inhibition is clinically highly significant, as it is the direct cause of notable adverse effects, including the development of metabolic acidosis and an increased risk of renal stone formation.[4]

3.1.4 Neuroprotective and Antioxidant Properties

Evidence from preclinical studies suggests that zonisamide may possess neuroprotective properties that are independent of its direct anticonvulsant activity.[32] It has been shown to act as an antioxidant, scavenging free radicals and protecting against oxidative stress-induced neuronal injury.[1] This is supported by findings in animal models where zonisamide prevented the reduction of dopamine and its metabolites in the striatum following exposure to the neurotoxin MPTP.[14]

3.2 Pharmacodynamics

The composite pharmacodynamic effect of zonisamide's multi-modal actions is the suppression of abnormal neuronal excitability, leading to an increase in seizure threshold and a reduction in the initiation and propagation of seizure activity.[9] These same mechanisms also underlie its adverse effect profile. The direct extension of its primary CNS-modulating activity results in common side effects such as somnolence, dizziness, and cognitive slowing. The most severe and life-threatening adverse reactions, such as SJS/TEN, DRESS, and other blood dyscrasias, are idiosyncratic events linked to its sulfonamide chemical structure and the potential for severe hypersensitivity.[9]

3.3 Pharmacokinetics (ADME)

The clinical use of zonisamide is heavily influenced by its unique pharmacokinetic profile, characterized by rapid absorption, extensive distribution into erythrocytes, and a very long elimination half-life.

3.3.1 Absorption

Following oral administration, zonisamide is rapidly and completely absorbed, exhibiting high oral bioavailability of approximately 95%.[4] In healthy volunteers, peak plasma concentrations (

Tmax​) are typically reached within 2 to 6 hours.[4] The presence of food delays the time to reach peak concentration but does not affect the overall extent of absorption (i.e., its bioavailability is unchanged).[4]

3.3.2 Distribution

Zonisamide has an apparent volume of distribution (Vd​/F) of approximately 1.45 L/kg.[9] Its distribution is defined by two key features:

1. Plasma Protein Binding: It is moderately bound to plasma proteins, primarily albumin, at approximately 40%. This binding is not significantly affected by the presence of therapeutic concentrations of other AEDs such as phenytoin, phenobarbital, or carbamazepine.[4]
2. Erythrocyte Binding: A defining pharmacokinetic characteristic of zonisamide is its extensive and high-affinity binding to erythrocytes (red blood cells). This results in a partitioning effect where the concentration of zonisamide in red blood cells is approximately 8-fold higher than in plasma.[4] This large erythrocyte reservoir is a primary contributor to the drug's exceptionally long half-life.

This binding to erythrocytes is also saturable.[4] This saturation phenomenon explains why the drug's pharmacokinetics become non-linear at high doses (e.g., >800 mg), as the erythrocyte reservoir becomes full, causing a disproportionate increase in free plasma concentrations.[9] It also underlies early clinical observations that monitoring of whole

blood concentrations might provide a more stable indicator of drug exposure than monitoring serum or plasma concentrations alone, as the latter can show greater inter-patient variability.[10] This suggests that standard therapeutic drug monitoring of plasma levels may not fully capture the total body drug load, a critical consideration in managing complex or refractory patients.

3.3.3 Metabolism

Zonisamide undergoes extensive hepatic metabolism, primarily via reductive and conjugative pathways, with oxidation playing only a minor role.[4] The major metabolic pathway is the reductive cleavage of the benzisoxazole ring by cytochrome P450 3A4 (CYP3A4) to form the open-ring metabolite, 2–sulfamoylacetylphenol (SMAP).[4] CYP2C19 and CYP3A5 may also contribute to this process to a lesser extent.[4] A secondary metabolic pathway involves acetylation via N-acetyl-transferases to form N-acetyl zonisamide.[9]

A clinically important feature is that zonisamide does not induce its own metabolism (auto-induction) and does not significantly induce or inhibit other major hepatic enzymes. This characteristic minimizes its potential to alter the metabolism of co-administered drugs, which is a favorable attribute in polypharmacy settings common in epilepsy treatment.[4]

3.3.4 Elimination

Zonisamide and its metabolites are eliminated primarily by the kidneys, with the majority of the dose recovered in the urine and only a small fraction in the feces.[9] Following administration of a radiolabeled dose, approximately 35% is excreted as unchanged zonisamide, 15% as N-acetyl zonisamide, and 50% as the glucuronide conjugate of SMAP.[9]

The elimination half-life of zonisamide is exceptionally long, averaging approximately 63 hours in plasma and an even longer 105 hours in red blood cells, due to the slow release from its erythrocyte reservoir.[2] This long half-life allows for convenient once- or twice-daily dosing regimens but also means that it takes approximately 14 days of consistent dosing to reach steady-state plasma concentrations.[2]

The plasma clearance of zonisamide is approximately 0.30–0.35 mL/min/kg in patients not receiving concomitant enzyme-inducing AEDs. This clearance is significantly increased (to approximately 0.5 mL/min/kg) in patients taking potent CYP3A4 inducers such as phenytoin, carbamazepine, or phenobarbital, which can necessitate dosage adjustments.[9]

Table 2: Key Pharmacokinetic Parameters of Zonisamide

Parameter	Value / Description	Source(s)
Oral Bioavailability	~95%	9
Time to Peak (Tmax)	2–6 hours (fasted); delayed by food	4
Plasma Protein Binding	~40%	4
Volume of Distribution (Vd/F)	~1.45 L/kg	9
Elimination Half-life	Plasma: ~63 hours; Erythrocytes: ~105 hours	4
Time to Steady State	~14 days	4
Metabolism Pathway	Hepatic; Reduction to SMAP and Acetylation	4
Primary Enzyme	Cytochrome P450 3A4 (CYP3A4)	4
Route of Excretion	Primarily renal	9
% Unchanged in Urine	~35%	9
Clearance (no inducers)	~0.30–0.35 mL/min/kg	9
Clearance (with inducers)	~0.5 mL/min/kg	9

Section 4: Clinical Efficacy and Therapeutic Applications

The clinical utility of zonisamide has been most rigorously established in the treatment of epilepsy, its primary indication. However, its broad pharmacological profile and observed clinical effects have prompted significant investigation and off-label use in a variety of other neurological and psychiatric conditions. This pattern of application demonstrates a form of "reverse translation," where the drug's known secondary actions and side effect profile have directly informed its exploration in new, mechanistically plausible therapeutic areas.

4.1 Approved Indication: Adjunctive Therapy for Partial-Onset Seizures

In the United States, zonisamide is approved by the FDA as an adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients aged 16 years and older.[1] Its efficacy for this indication was established in three pivotal multicenter, placebo-controlled, double-blind clinical trials conducted in patients with refractory epilepsy.[34]

These trials enrolled patients who were experiencing at least four partial-onset seizures per month despite receiving stable, therapeutic doses of one or two other AEDs.[34] Patients were randomized to receive either zonisamide or placebo as add-on therapy. The study protocols involved a dose-titration phase followed by a maintenance phase of at least 12 weeks.[18] The primary efficacy endpoint was the median percent reduction in partial seizure frequency from baseline, with the responder rate (the proportion of patients achieving a 50% or greater reduction in seizure frequency) serving as a key secondary endpoint.[34]

The results from these trials consistently demonstrated the statistically significant superiority of zonisamide over placebo. For instance, in a large US trial, patients receiving a maintenance dose of 400 mg/day of zonisamide experienced a median reduction in seizure frequency of 40.5%, compared to only a 9.0% reduction in the placebo group (p = 0.0009). The responder rate in this study was 42% for the zonisamide group.[34] The trials also established a clear dose-response relationship, with 100 mg/day identified as the minimal effective dose and 400 mg/day as the most effective dose studied.[37] Efficacy was found to be comparable whether the total daily dose was administered once daily or divided into two daily doses.[34]

Table 3: Summary of Pivotal Efficacy Trials of Zonisamide in Partial-Onset Seizures

Study Identifier / Reference	Design	Patient Population (n)	Treatment Arms (Dose)	Median % Seizure Reduction (Drug vs. Placebo)	Responder Rate (Drug vs. Placebo)
Study 1 34	Randomized, Double-Blind, Placebo-Controlled, Dose-Response	203 adults with refractory partial-onset seizures	Zonisamide 100, 200, 400 mg/day vs. Placebo	40.5% (at 400 mg) vs. 9.0%	41.8% (at 400 mg) vs. 22.2%
Study 2 34	Randomized, Double-Blind, Placebo-Controlled	141 adults with refractory partial-onset seizures	Zonisamide (titrated) vs. Placebo	29.6% vs. -3.2%	29.0% vs. 15.0%
Study 3 34	Randomized, Double-Blind, Placebo-Controlled	133 adults with refractory partial-onset seizures	Zonisamide (titrated) vs. Placebo	27.2% vs. -1.1%	28.0% vs. 12.0%

4.2 Off-Label and Investigational Uses

The multifaceted pharmacology of zonisamide has led to its use and investigation in a wide range of conditions beyond its approved indication.

4.2.1 Epilepsy Syndromes and Other Seizure Types

Zonisamide is frequently used off-label in the management of severe epilepsy syndromes, including infantile spasms (West syndrome), Lennox-Gastaut syndrome, and progressive myoclonic epilepsy.[2] Clinical trials have formally investigated its utility in other seizure types. A study of adjunctive zonisamide for primary generalized tonic-clonic seizures (NCT00692003) has been conducted.[39] Another trial in patients with myoclonus-dystonia (NCT01806805) demonstrated that zonisamide significantly improved action myoclonus and myoclonus-related functional disability compared to placebo.[40]

4.2.2 Parkinson's Disease (PD)

The exploration of zonisamide in PD is a direct consequence of its known effects on dopaminergic neurotransmission.[9] It is approved in Japan as an adjunct to levodopa for improving motor symptoms, typically at low doses of 25–50 mg per day.[13] Its mechanism in PD is thought to involve not only the facilitation of dopamine release but also potential inhibition of monoamine oxidase-B (MAO-B) and neuroprotective effects.[20]

4.2.3 Metabolic and Eating Disorders

The well-documented adverse effect of anorexia and weight loss has been repurposed as a potential therapeutic effect. Zonisamide is used off-label to treat binge-eating disorder, often in combination with cognitive behavioral therapy, where it is thought to act on appetite centers in the brain.[25] It has also been formally studied for

obesity, with trials showing significant positive effects on body weight loss, although a planned combination product (bupropion/zonisamide, brand name Empatic) had its development discontinued.[13]

4.2.4 Migraine Prevention

Leveraging the same neuronal stabilizing properties that are effective in epilepsy, zonisamide is used off-label as a prophylactic treatment for migraine headaches. It is often considered as an alternative for patients who cannot tolerate or do not respond to topiramate, another AED used for migraine prevention.[2]

4.2.5 Other Investigational Uses

The CNS-modulating effects of zonisamide have prompted exploration in other areas. A Phase 2 clinical trial (NCT01765608) has been completed for the treatment of obstructive sleep apnea.[44] A Phase 1/2 trial (NCT01137890) has been completed to evaluate its effect on

cocaine addiction, likely exploring its impact on the brain's dopaminergic reward pathways.[45] Additionally, small open-label trials have suggested a potential benefit in treating

tardive dyskinesia, and it has been used off-label by psychiatrists as a mood stabilizer for bipolar depression.[2]

Section 5: Safety Profile and Risk Management

The clinical application of zonisamide requires a thorough understanding of its safety profile, which is characterized by a range of adverse effects from common, manageable CNS symptoms to rare, but severe and potentially fatal, systemic reactions. A sophisticated approach to risk management recognizes that these risks are not a random collection of events but fall into distinct clusters that are mechanistically linked to the drug's fundamental chemical structure and pharmacological actions.

5.1 Adverse Drug Reactions (ADRs)

The most common adverse drug reactions (ADRs) associated with zonisamide are predominantly related to its effects on the central nervous system. These include somnolence (drowsiness), dizziness, ataxia (impaired coordination), agitation or irritability, and cognitive difficulties such as problems with memory, concentration, or mental slowing. Anorexia (loss of appetite), which frequently leads to weight loss, is also a very common side effect.[2] A more comprehensive list of reported adverse effects, categorized by system organ class, includes gastrointestinal disturbances (nausea, diarrhea), psychiatric symptoms (depression, psychosis), and various other less frequent events.[25]

5.2 Warnings, Precautions, and Contraindications

Zonisamide is contraindicated in patients with a known history of hypersensitivity to zonisamide or any other sulfonamide-containing drugs.[4] Beyond this absolute contraindication, several serious warnings and precautions demand careful patient selection and monitoring. These risks can be understood as three mechanistically-linked clusters.

5.2.1 Cluster 1: Sulfonamide Hypersensitivity Reactions

As a sulfonamide derivative, zonisamide carries an inherent risk of inducing severe, idiosyncratic hypersensitivity reactions, which can be life-threatening. This risk is highlighted in a boxed warning on some international labels and is a critical consideration for prescribers.[4] These reactions include:

• Serious Skin Reactions: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare but potentially fatal mucocutaneous reactions. Patients must be counseled to report any new rash immediately, particularly within the first few weeks to months of initiating therapy. Zonisamide should be discontinued at the first sign of a rash unless it is clearly not drug-related.[6]
• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Also known as multi-organ hypersensitivity, DRESS is another severe, potentially fatal reaction characterized by fever, rash, eosinophilia, and systemic organ involvement (e.g., hepatitis, nephritis). It requires immediate drug discontinuation and supportive care.[4]
• Serious Hematologic Events: Rare cases of aplastic anemia and agranulocytosis have been reported in patients taking zonisamide, consistent with risks associated with other sulfonamides.[6]

5.2.2 Cluster 2: Carbonic Anhydrase Inhibition Effects

Zonisamide's weak inhibition of carbonic anhydrase is directly responsible for a distinct set of metabolic and renal adverse effects.

• Metabolic Acidosis: By inhibiting renal carbonic anhydrase, zonisamide can impair bicarbonate reabsorption, leading to a non-anion-gap metabolic acidosis.[2] The FDA issued a specific safety alert regarding this risk in 2009.[6] The risk is elevated in patients with predisposing conditions (e.g., renal disease, severe respiratory disorders, diarrhea, ketogenic diet) and may be more frequent and severe in children.[6] Chronic, untreated metabolic acidosis can have long-term sequelae, including osteopenia, osteoporosis, and rickets, and can contribute to kidney stone formation.[12] It is recommended that serum bicarbonate levels be measured at baseline and periodically during treatment.[4]
• Kidney Stones (Nephrolithiasis): The risk of developing kidney stones is increased in patients taking zonisamide, occurring in approximately 1-4% of individuals, often after 6 to 12 months of therapy.[2] This risk is also linked to its carbonic anhydrase inhibitory effect, which can alter urine pH and solute concentration. Patients, particularly those with a personal or family history of kidney stones, should be counseled on the importance of maintaining adequate hydration (e.g., drinking 6-8 glasses of water daily) to mitigate this risk.[4]

5.2.3 Cluster 3: Central Nervous System Effects

The therapeutic CNS-modulating activity of zonisamide can also lead to significant adverse effects.

• Suicidal Behavior and Ideation: In line with a class-wide warning for all antiepileptic drugs issued by the FDA in 2008, zonisamide is associated with an increased risk of suicidal thoughts and behavior.[4] Patients, their families, and caregivers must be advised to monitor for any emergence or worsening of depression, unusual changes in mood or behavior, or suicidality.[6]
• Oligohidrosis and Hyperthermia: A notable and potentially dangerous adverse effect is decreased sweating (oligohidrosis), which can impair thermoregulation and lead to hyperthermia and heat stroke. This risk is particularly pronounced in pediatric patients and during periods of warm weather or strenuous exercise.[4]
• Acute Myopia and Secondary Angle-Closure Glaucoma: Cases of an idiosyncratic syndrome consisting of acute myopia and secondary angle-closure glaucoma have been reported. Symptoms include an acute onset of decreased visual acuity and/or ocular pain. This condition requires immediate discontinuation of zonisamide to prevent permanent vision loss.[8]

5.3 Drug-Drug and Drug-Food Interactions

Zonisamide is subject to several clinically significant interactions that can affect its efficacy and safety.

5.3.1 Pharmacokinetic Interactions

• CYP3A4 Inducers: The clearance of zonisamide is significantly increased when it is co-administered with potent inducers of the CYP3A4 enzyme, such as the AEDs phenytoin, carbamazepine, and phenobarbital. This interaction reduces zonisamide's plasma concentrations and half-life, potentially leading to a loss of efficacy. Patients on these concomitant medications may require higher doses of zonisamide to achieve a therapeutic effect.[2]
• CYP3A4 Inhibitors: Conversely, strong inhibitors of CYP3A4, such as ketoconazole or certain macrolide antibiotics, can decrease the metabolism of zonisamide, leading to elevated plasma levels and an increased risk of dose-related toxicity. A dose reduction of zonisamide may be necessary in these situations.[4]
• Effect of Zonisamide on Other Drugs: As zonisamide is not a significant enzyme inducer or inhibitor itself, it generally does not cause clinically meaningful changes in the plasma concentrations of other drugs, a favorable characteristic in polytherapy.[4]

5.3.2 Pharmacodynamic Interactions

• CNS Depressants: There is a potential for additive CNS depressant effects (e.g., somnolence, dizziness, cognitive impairment) when zonisamide is taken with other substances that act on the CNS, including alcohol, benzodiazepines, opioids, and other sedating medications. Patients should be advised to avoid or limit the use of alcohol while on zonisamide therapy.[9]
• Other Carbonic Anhydrase Inhibitors: The concurrent use of zonisamide with other carbonic anhydrase inhibitors, such as topiramate or acetazolamide, can potentiate the risk of developing metabolic acidosis and kidney stones. This combination should be used with caution and requires close monitoring.[9]

5.3.3 Drug-Food Interactions

Zonisamide can be administered with or without food.[8] While food can delay the time it takes to reach peak plasma concentration, it does not impact the overall bioavailability of the drug.[4] Some sources advise caution with consuming large amounts of grapefruit juice, as it is a known inhibitor of intestinal CYP3A4 and could theoretically increase zonisamide absorption and the risk of adverse effects.[4]

Table 4: Clinically Significant Drug Interactions with Zonisamide

Interacting Drug/Class	Mechanism	Clinical Effect	Management Recommendation	Source(s)
CYP3A4 Inducers (e.g., Phenytoin, Carbamazepine, Phenobarbital, Rifampin)	Increased metabolic clearance of zonisamide via CYP3A4 induction.	Decreased zonisamide plasma concentration and half-life; potential loss of efficacy.	Monitor for efficacy. May require higher zonisamide maintenance dose and faster titration.	9
CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin)	Decreased metabolic clearance of zonisamide via CYP3A4 inhibition.	Increased zonisamide plasma concentration; increased risk of dose-related adverse effects.	Monitor for toxicity. May require lower zonisamide dose or slower titration.	4
Other Carbonic Anhydrase Inhibitors (e.g., Topiramate, Acetazolamide)	Additive pharmacodynamic effect (inhibition of carbonic anhydrase).	Increased risk of metabolic acidosis and nephrolithiasis.	Use with caution. Monitor serum bicarbonate and for symptoms of kidney stones.	9
CNS Depressants (e.g., Alcohol, Benzodiazepines, Opioids)	Additive pharmacodynamic effect (CNS depression).	Increased somnolence, dizziness, and cognitive/motor impairment.	Counsel patient to avoid or limit alcohol. Use with caution with other sedating drugs.	50

5.4 Toxicology and Overdose Management

Experience with acute zonisamide overdose is limited, but available case reports suggest a relatively benign clinical course with supportive care, even following massive ingestions of up to 12.6 g.[47] There is no specific antidote for zonisamide toxicity.

The clinical presentation of an overdose is an extension of the drug's known pharmacological effects. The most prominent features are related to CNS depression and may include profound somnolence, progressing to coma, as well as ataxia and vomiting.[46] Cardiovascular effects such as bradycardia and hypotension, as well as respiratory depression, have also been reported.[46] Due to its carbonic anhydrase inhibitory activity, a normal-anion-gap metabolic acidosis and polyuria may develop and persist for several days.[47]

Management of zonisamide overdose is entirely supportive. Key interventions include:

• Standard decontamination measures if appropriate and within the therapeutic window.
• Close monitoring of vital signs, level of consciousness, and respiratory status.
• Airway protection, including endotracheal intubation and mechanical ventilation, if the patient is comatose or has significant respiratory depression.[47]
• Hemodynamic support with intravenous fluids and, if necessary, vasopressor agents (e.g., catecholamines) for persistent hypotension.[53]
• Monitoring of serum electrolytes and acid-base status, with correction of metabolic acidosis as clinically indicated.

Given the exceptionally long elimination half-life of zonisamide, patients require a prolonged period of observation and supportive care until the drug is cleared and symptoms resolve.[54]

Section 6: Guidance for Clinical Practice

The effective and safe use of zonisamide in a clinical setting requires an individualized approach to therapy. Prescribing decisions must be guided by the drug's specific pharmacokinetic properties, its established efficacy data, and a comprehensive understanding of its potential risks. Dosing and titration strategies, in particular, must be adapted based on key patient-specific factors, most notably age and the use of concomitant medications that can alter its metabolism.

6.1 Dosing, Titration, and Administration

Zonisamide is available as hard capsules (Zonegran® and generics) in 25 mg, 50 mg, and 100 mg strengths, and as a 100 mg/5mL oral suspension (Zonisade™).[6] The capsules should be swallowed whole and not crushed or chewed.[8]

6.1.1 Adult Dosing for Adjunctive Therapy

• Initiation: The recommended starting dose for adults is 100 mg administered once daily.[2]
• Titration: The dose should be titrated slowly to minimize adverse effects. After two weeks at the initial dose, the daily dose can be increased to 200 mg (administered as 100 mg twice daily). Subsequent dose escalations should be made in increments of 100 mg at intervals of no less than two weeks to allow for steady-state concentrations to be approached.[2]
• Maintenance: The usual effective maintenance dose range is 100 mg to 600 mg per day. Clinical trial data suggest that doses above 400 mg per day are not associated with a substantial increase in therapeutic benefit but do increase the incidence of adverse effects.[24]
• Administration: The total daily dose can be administered once daily or divided into two doses. A once-daily regimen, often taken at bedtime, may be preferred to help manage CNS side effects like dizziness and somnolence.[8] The drug can be taken with or without food.[38]
• Discontinuation: Zonisamide therapy should not be discontinued abruptly, as this carries a risk of precipitating withdrawal seizures or status epilepticus. A gradual dose reduction is mandatory. A common approach in clinical studies has been to reduce the dose by 100 mg at weekly intervals.[46]

The speed of titration must be personalized. A slower titration schedule (e.g., bi-weekly increments) is appropriate for most patients, especially those not taking enzyme-inducing drugs or those with renal or hepatic impairment. Conversely, a faster titration (e.g., weekly increments) may be considered in patients taking potent CYP3A4-inducing AEDs, as they will clear zonisamide more rapidly.[2] This demonstrates that a clinician cannot use a rigid protocol; assessment of the patient's concomitant medication list is a critical prerequisite to designing an appropriate titration plan.

6.2 Use in Special Populations

6.2.1 Pediatric Population

• Regulatory Status: In the US, zonisamide is approved for adjunctive use only in patients aged 16 years and older.[7] The EMA has a broader approval for adjunctive use in children from 6 years of age.[35] Therefore, use in children under 16 in the US is considered off-label.
• Specific Risks: Children are at a demonstrably higher risk for developing oligohidrosis (decreased sweating) and subsequent hyperthermia, as well as metabolic acidosis.[4] Close monitoring for these effects is essential.
• Pharmacokinetics and Dosing: Pharmacokinetic studies have shown that young children, particularly those under 5 years of age, have a significantly increased clearance of zonisamide (approximately 1.7-fold higher than older patients).[35] This means that to achieve therapeutic plasma concentrations, younger children require higher weight-normalized doses (mg/kg) than adolescents or adults. Off-label dosing is typically weight-based, often in the range of 6–8 mg/kg/day, with a maximum of 500 mg/day.[55]

6.2.2 Geriatric Population

There is limited specific data on zonisamide use in the elderly. However, general geriatric prescribing principles apply. Dose selection should be cautious, typically starting at the lowest end of the dosing range, with a slower titration schedule. This is to account for the higher likelihood of age-related declines in renal, hepatic, and cardiac function, as well as the increased prevalence of polypharmacy.[2]

6.2.3 Renal and Hepatic Impairment

• Renal Impairment: Zonisamide and its metabolites are excreted by the kidneys. In patients with impaired renal function, clearance is reduced. Therefore, the drug should be used with caution, employing a slower titration and more frequent monitoring.[2] Administration is not recommended in patients with severe renal impairment (Creatinine Clearance, CrCl < 20 mL/min). Zonisamide should be discontinued if a patient develops acute renal failure or a clinically significant, sustained increase in serum creatinine.[4]
• Hepatic Impairment: The use of zonisamide in patients with hepatic impairment has not been formally studied. As it is extensively metabolized by the liver, caution must be exercised in patients with mild to moderate hepatic impairment, with a slower titration recommended. Its use is not recommended in patients with severe hepatic impairment.[4]

6.2.4 Pregnancy and Lactation

• Pregnancy: Zonisamide is classified as Pregnancy Category C. It is known to rapidly cross the human placenta. While human data on teratogenicity are limited, animal studies have shown adverse fetal effects. The potential benefits of maintaining seizure control in the mother must be carefully weighed against the potential risks to the fetus. Women of childbearing potential should be advised to use effective contraception during therapy.[2]
• Lactation: Zonisamide is excreted into breast milk, and infant serum levels can become significant. Although adverse effects have not been definitively reported in breastfed infants, the available data are limited. Caution is advised, and if a mother chooses to breastfeed while taking zonisamide, the infant should be closely monitored for adverse effects such as unusual sleepiness, poor feeding, or inadequate weight gain.[4]

Section 7: Conclusion and Future Perspectives

7.1 Concluding Summary

Zonisamide has secured a durable place in the therapeutic armamentarium for epilepsy as a second-generation antiepileptic drug. Its value lies in its unique 1,2-benzisoxazole structure and its multi-modal mechanism of action, which confers broad-spectrum efficacy, particularly as an adjunctive treatment for patients with refractory partial-onset seizures. The drug’s favorable pharmacokinetic profile, most notably its long elimination half-life, allows for convenient once- or twice-daily dosing schedules that can significantly enhance patient adherence.

However, the clinical utility of zonisamide is intrinsically linked to, and must be balanced against, a significant and mechanistically predictable safety profile. The primary risks are clustered around three core properties of the molecule: its sulfonamide chemical structure, which carries the potential for severe hypersensitivity reactions; its weak but clinically relevant inhibition of carbonic anhydrase, which predisposes patients to metabolic acidosis and nephrolithiasis; and its direct modulatory effects on the central nervous system, which can lead to cognitive side effects and an increased risk of suicidal ideation. Optimal use of zonisamide therefore demands careful patient selection, proactive monitoring for these specific risks, and comprehensive patient counseling.

7.2 Future Perspectives and Unanswered Questions

Despite being on the market for several decades, zonisamide continues to be an active area of clinical and scientific investigation, with several unanswered questions and avenues for future development.

• Expansion of Therapeutic Indications: Zonisamide has shown considerable promise in a number of off-label and investigational uses, including Parkinson's disease, certain severe epilepsy syndromes, and mood disorders. The evidence for these applications, however, is often derived from smaller trials, open-label studies, or regional data (as with PD in Japan). There is a clear need for large-scale, well-designed, randomized controlled trials to definitively establish its efficacy and safety in these conditions and potentially expand its approved indications globally.
• Optimization of Therapeutic Drug Monitoring (TDM): The unique pharmacokinetic behavior of zonisamide, characterized by its high-affinity, saturable binding to erythrocytes, presents a compelling area for further research. Early clinical data suggested that monitoring whole blood concentrations might provide a more stable and clinically relevant measure of drug exposure than standard plasma or serum level monitoring.[10] Investigating the clinical utility of whole blood TDM could lead to more precise dose optimization, particularly in complex cases, such as in patients on multiple interacting drugs or those who show a poor correlation between plasma level and clinical response.
• Elucidation of Neuroprotective Effects: The neuroprotective and antioxidant properties demonstrated in preclinical models are intriguing.[5] Further research is warranted to determine if these effects translate into clinically meaningful, disease-modifying outcomes in chronic conditions like epilepsy or in neurodegenerative disorders such as Parkinson's disease. Identifying a clear neuroprotective benefit could fundamentally reposition zonisamide in treatment algorithms.
• Continued Formulation Development: The recent approval of an oral suspension (Zonisade™) has addressed a major clinical need for specific patient populations.[22] Future research could explore the potential for other formulations, such as a parenteral (intravenous) formulation, which could be valuable in the acute care setting for treating conditions like status epilepticus where oral administration is not feasible.
• Ongoing Clinical Research: The continued initiation of new clinical trials, such as a real-world, prospective study evaluating the efficacy and safety of add-on zonisamide in focal epilepsy (NCT06374966), underscores the ongoing interest in refining its place in therapy.[56] Such studies are crucial for gathering long-term, real-world evidence that complements the data from initial registration trials and helps to better define its role in contemporary clinical practice.

Works cited

1. Zonisamide | C8H8N2O3S | CID 5734 - PubChem, accessed July 25, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Zonisamide
2. Zonisamide CAS#: 68291-97-4 - ChemicalBook, accessed July 25, 2025, https://m.chemicalbook.com/ProductChemicalPropertiesCB0252441_EN.htm
3. go.drugbank.com, accessed July 25, 2025, https://go.drugbank.com/drugs/DB00909#:~:text=Zonisamide%20is%20a%20sulfonamide%20anticonvulsant%20used%20as%20an%20adjunctive,adults%20with%20partial%2Donset%20seizures.&text=Zonisamide%20may%20act%20by%20blocking,binding%20allosterically%20to%20GABA%20receptors.
4. Zonisamide - StatPearls - NCBI Bookshelf, accessed July 25, 2025, https://www.ncbi.nlm.nih.gov/books/NBK507903/
5. What is the mechanism of Zonisamide? - Patsnap Synapse, accessed July 25, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-zonisamide
6. Zonisamide | Anti-Seizure Medication - Epilepsy Foundation, accessed July 25, 2025, https://www.epilepsy.com/tools-resources/seizure-medication-list/zonisamide
7. Zonisamide | Neurology Clinical Practice, accessed July 25, 2025, https://www.neurology.org/doi/10.1212/CPJ.0000000000200210
8. Zonegran (Zonisamide): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 25, 2025, https://www.rxlist.com/zonegran-drug.htm
9. Zonisamide: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 25, 2025, https://go.drugbank.com/drugs/DB00909
10. Pharmacokinetics of Zonisamide ; Saturable Distribution into Human and Rat Erythrocytes and into Rat Brain - J-Stage, accessed July 25, 2025, https://www.jstage.jst.go.jp/article/bpb1978/15/8/15_8_409/_article
11. zonisade - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214273s000lbl.pdf
12. Zonisamide (Zonegran) Uses & Side Effects - Epilepsy Medication, accessed July 25, 2025, https://www.cureepilepsy.org/understanding-epilepsy/treatments/epilepsy-medications/zonisamide/
13. Zonisamide - Wikipedia, accessed July 25, 2025, https://en.wikipedia.org/wiki/Zonisamide
14. Zonisamide (CAS 68291-97-4) - Cayman Chemical, accessed July 25, 2025, https://www.caymanchem.com/product/24183/zonisamide
15. Development of Antiepileptic Drugs throughout History: From Serendipity to Artificial Intelligence - MDPI, accessed July 25, 2025, https://www.mdpi.com/2227-9059/11/6/1632
16. NDA 020789/S-030 FDA Approved Labeling Text dated 9/22/2011 Page 1 - ZONEGRAN, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020789s030lbl.pdf
17. SAFETY DATA SHEET ZONISAMIDE CAPSULES USP Pack Size - Viona Pharmaceuticals, accessed July 25, 2025, https://vionausa.com/wp-content/uploads/2022/09/SDS-Zonisamide-Capsules.pdf
18. Zonegran, INN-Zonisamide - EMA, accessed July 25, 2025, https://www.ema.europa.eu/en/documents/scientific-discussion/zonegran-epar-scientific-discussion_en.pdf
19. Drug Approval Package: Zonegran (Zonisomide) NDA #20-789, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020789_Zonegran.cfm
20. Zonisamide: A review of the clinical and experimental evidence for its use in Parkinson's disease - PubMed Central, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3847242/
21. Zonisamide - Eisai Co Ltd - AdisInsight - Springer, accessed July 25, 2025, https://adisinsight.springer.com/drugs/800009249
22. Eton Pharmaceuticals Announces FDA Approval of ZONISADE™ (Zonisamide Oral Suspension), accessed July 25, 2025, https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-fda-approval-zonisadetm/
23. Zonisade (zonisamide) FDA Approval History - Drugs.com, accessed July 25, 2025, https://www.drugs.com/history/zonisade.html
24. Zonisamide (oral route) - Side effects & dosage - Mayo Clinic, accessed July 25, 2025, https://www.mayoclinic.org/drugs-supplements/zonisamide-oral-route/description/drg-20066787
25. Zonisamide: Seizure Uses, Warnings, Side Effects, Dosage, accessed July 25, 2025, https://www.medicinenet.com/zonisamide/article.htm
26. ZONISAMIDE - DailyMed, accessed July 25, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=31b97f07-9783-479d-b448-b272610a2f36
27. Zonisamide USP Reference Standard CAS 68291-97-4 Sigma-Aldrich, accessed July 25, 2025, https://www.sigmaaldrich.com/US/en/product/usp/1725003
28. [Zonisamide (200 mg)] - CAS [68291-97-4] - USP Store, accessed July 25, 2025, https://store.usp.org/product/1725003
29. Zonisamide | CAS 68291-97-4 | LGC Standards, accessed July 25, 2025, https://www.lgcstandards.com/VC/en/Zonisamide/p/MM1379.00
30. SAFETY DATA SHEET - Fisher Scientific, accessed July 25, 2025, https://www.fishersci.com/store/msds?partNumber=AC465042500&productDescription=ZONISAMIDE+250MG&vendorId=VN00032119&countryCode=US&language=en
31. www.accessdata.fda.gov, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020789s012lbl.pdf
32. Clinical pharmacology and mechanism of action of zonisamide - PubMed, accessed July 25, 2025, https://pubmed.ncbi.nlm.nih.gov/17762320/
33. Zonisamide: chemistry, mechanism of action, and pharmacokinetics - PubMed, accessed July 25, 2025, https://pubmed.ncbi.nlm.nih.gov/15511691/
34. ZONEGRAN® (zonisamide) capsules - accessdata.fda.gov, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020789s022s025lbl.pdf
35. Zonisamide: Pharmacokinetics, Efficacy, and Adverse Events in Children with Epilepsy - Thieme Connect, accessed July 25, 2025, https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0034-1387815.pdf
36. www.neurology.org, accessed July 25, 2025, https://www.neurology.org/doi/10.1212/WNL.57.10.1774#:~:text=Results%3A%20At%20400%20mg%2Fd,)%20in%2042%25%20of%20patients.%2520in%252042%2525%2520of%2520patients.&sa=D&source=editors&ust=1753441100415621&usg=AOvVaw294yXzAflIpUQSSgT7vkJ3)
37. Randomized controlled trial of zonisamide for the treatment of ..., accessed July 25, 2025, https://www.neurology.org/doi/10.1212/WNL.57.10.1774
38. Zonisamide for Epilepsy Management - Uses, Side Effects & More - Marley Drug, accessed July 25, 2025, https://www.marleydrug.com/blog/zonisamide
39. Study Details | Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures, accessed July 25, 2025, https://clinicaltrials.gov/study/NCT00692003?term=NCT00154076%20NCT00165828%20NCT00215592%20NCT00292461%20NCT00477295%20NCT00566254%20NCT00659958%20NCT00692003%20NCT00693017%20NCT00713622%20NCT00848549%20NCT01127165%20NCT01127256%20NCT01140867%20NCT01546688%20NCT02205931%20NCT02707965&rank=10
40. A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia, accessed July 25, 2025, https://www.neurology.org/doi/10.1212/WNL.0000000000002631
41. Study Details | Efficacy Trial of Zonisamide for Myoclonus Dystonia | ClinicalTrials.gov, accessed July 25, 2025, https://clinicaltrials.gov/study/NCT01806805
42. www.medicinenet.com, accessed July 25, 2025, https://www.medicinenet.com/zonisamide/article.htm#:~:text=Zonisamide%20is%20also%20used%20off,appetite%20center%20in%20the%20brain.
43. Zonisamide - brand name list from Drugs.com, accessed July 25, 2025, https://www.drugs.com/ingredient/zonisamide.html
44. Obstructive Sleep Apnea Completed Phase 2 Trials for Zonisamide (DB00909) - DrugBank, accessed July 25, 2025, https://go.drugbank.com/indications/DBCOND0030088/clinical_trials/DB00909?phase=2&status=completed
45. Cocaine Addictions Completed Phase 1 / 2 Trials for Zonisamide (DB00909) - DrugBank, accessed July 25, 2025, https://go.drugbank.com/indications/DBCOND0038227/clinical_trials/DB00909?phase=1%2C2&status=completed
46. Zonisamide: MedlinePlus Drug Information, accessed July 25, 2025, https://medlineplus.gov/druginfo/meds/a603008.html
47. Moderate toxic effects following acute zonisamide overdose - PubMed, accessed July 25, 2025, https://pubmed.ncbi.nlm.nih.gov/21463969/
48. Boxed warning for metoclopramide, alert for zonisamide | I.M. Matters from ACP, accessed July 25, 2025, https://immattersacp.org/archives/2009/04/fda.htm
49. Zonisamide (Zonegran, Zonisade): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed July 25, 2025, https://www.webmd.com/drugs/2/drug-18137/zonisamide-oral/details
50. What is Zonisamide used for? - Patsnap Synapse, accessed July 25, 2025, https://synapse.patsnap.com/article/what-is-zonisamide-used-for
51. Zonisamide and Alcohol/Food Interactions - Drugs.com, accessed July 25, 2025, https://www.drugs.com/food-interactions/zonisamide.html
52. Zonisamide: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed July 25, 2025, https://www.medcentral.com/drugs/monograph/18137-301027/zonisamide-oral
53. Complete Recovery After Acute Zonisamide Overdose in an Adolescent Female - PubMed, accessed July 25, 2025, https://pubmed.ncbi.nlm.nih.gov/27749631/
54. 1 Moderate Toxic Effects following Acute Zonisamide Overdose - ZORA (Zurich Open Repository and Archive), accessed July 25, 2025, https://www.zora.uzh.ch/60349/1/PMID_21463969_Zonisamide.pdf
55. Zonisamide Viatris | EMA, accessed July 25, 2025, https://www.ema.europa.eu/en/documents/product-information/zonisamide-viatris-epar-product-information_en.pdf
56. Real-world Study of Efficacy and Safety of Zonisamide in add-on Therapy for Patients With Focal Epilepsy | ClinicalTrials.gov, accessed July 25, 2025, https://www.clinicaltrials.gov/study/NCT06374966?term=ZONISAMIDE&rank=9